{
  "functional_evidence_assessment": [
    {
      "variant_id": {
        "Gene": "PARKIN",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": 418
        },
        "variant_string_id": "PARKIN C418R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin mutations abolish the ability of parkin to control p53 transcription.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that parkin mutations lead to loss of function in controlling p53 transcription, which is a key aspect of the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses luciferase reporter assays and Western blotting to evaluate the impact of parkin mutations on p53 transcriptional activity.",
          "judgment": "Yes",
          "reasoning": "These assays are appropriate for evaluating transcriptional regulation and protein expression, which are relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Experiments include wild-type parkin as a control and are performed in triplicate.\n\nStep 3c: Variant Controls: Known pathogenic variants such as C441R and R256C were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: The paper states that wild-type parkin was used as a control, and experiments were performed in triplicate.\n\nStep 3c: Variant Controls: The paper includes known pathogenic variants as controls, which strengthens the reliability of the functional evidence."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Step 4b: No OddsPath Calculation: The study does not provide a direct OddsPath calculation but reports significant differences in p53 activity and expression.",
          "judgment": "Yes",
          "reasoning": "Step 4b: No OddsPath Calculation: While no OddsPath is calculated, the study provides sufficient statistical evidence of significant differences."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The C418R mutation significantly impairs parkin's ability to control p53 transcription, leading to increased p53 activity and expression. This is supported by robust experimental design and controls, indicating moderate pathogenic evidence."
    },
    {
      "variant_id": {
        "Gene": "PARKIN",
        "Protein_Change": {
          "ref": "C",
          "alt": "R",
          "position": 441
        },
        "variant_string_id": "PARKIN C441R"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin mutations abolish the ability of parkin to control p53 transcription.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that parkin mutations lead to loss of function in controlling p53 transcription, which is a key aspect of the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses luciferase reporter assays and Western blotting to evaluate the impact of parkin mutations on p53 transcriptional activity.",
          "judgment": "Yes",
          "reasoning": "These assays are appropriate for evaluating transcriptional regulation and protein expression, which are relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Experiments include wild-type parkin as a control and are performed in triplicate.\n\nStep 3c: Variant Controls: Known pathogenic variants such as C418R and R256C were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: The paper states that wild-type parkin was used as a control, and experiments were performed in triplicate.\n\nStep 3c: Variant Controls: The paper includes known pathogenic variants as controls, which strengthens the reliability of the functional evidence."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Step 4b: No OddsPath Calculation: The study does not provide a direct OddsPath calculation but reports significant differences in p53 activity and expression.",
          "judgment": "Yes",
          "reasoning": "Step 4b: No OddsPath Calculation: While no OddsPath is calculated, the study provides sufficient statistical evidence of significant differences."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The C441R mutation significantly impairs parkin's ability to control p53 transcription, leading to increased p53 activity and expression. This is supported by robust experimental design and controls, indicating moderate pathogenic evidence."
    },
    {
      "variant_id": {
        "Gene": "PARKIN",
        "Protein_Change": {
          "ref": "K",
          "alt": "N",
          "position": 161
        },
        "variant_string_id": "PARKIN K161N"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin mutations abolish the ability of parkin to control p53 transcription.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that parkin mutations lead to loss of function in controlling p53 transcription, which is a key aspect of the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses luciferase reporter assays and Western blotting to evaluate the impact of parkin mutations on p53 transcriptional activity.",
          "judgment": "Yes",
          "reasoning": "These assays are appropriate for evaluating transcriptional regulation and protein expression, which are relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Experiments include wild-type parkin as a control and are performed in triplicate.\n\nStep 3c: Variant Controls: Known pathogenic variants such as C418R and R256C were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: The paper states that wild-type parkin was used as a control, and experiments were performed in triplicate.\n\nStep 3c: Variant Controls: The paper includes known pathogenic variants as controls, which strengthens the reliability of the functional evidence."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Step 4b: No OddsPath Calculation: The study does not provide a direct OddsPath calculation but reports significant differences in p53 activity and expression.",
          "judgment": "Yes",
          "reasoning": "Step 4b: No OddsPath Calculation: While no OddsPath is calculated, the study provides sufficient statistical evidence of significant differences."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The K161N mutation significantly impairs parkin's ability to control p53 transcription, leading to increased p53 activity and expression. This is supported by robust experimental design and controls, indicating moderate pathogenic evidence."
    },
    {
      "variant_id": {
        "Gene": "PARKIN",
        "Protein_Change": {
          "ref": "R",
          "alt": "C",
          "position": 256
        },
        "variant_string_id": "PARKIN R256C"
      },
      "functional_evidence_aim": "Pathogenic",
      "assessment_steps": [
        {
          "step_name": "Step 1: Define the disease mechanism",
          "extracted_paper_info": "Parkin mutations abolish the ability of parkin to control p53 transcription.",
          "judgment": "Yes",
          "reasoning": "The paper clearly defines that parkin mutations lead to loss of function in controlling p53 transcription, which is a key aspect of the disease mechanism."
        },
        {
          "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
          "extracted_paper_info": "The study uses luciferase reporter assays and Western blotting to evaluate the impact of parkin mutations on p53 transcriptional activity.",
          "judgment": "Yes",
          "reasoning": "These assays are appropriate for evaluating transcriptional regulation and protein expression, which are relevant to the disease mechanism."
        },
        {
          "step_name": "Step 3: Evaluate validity of specific instances of assays",
          "extracted_paper_info": "Step 3a: Basic Controls and Replicates: Experiments include wild-type parkin as a control and are performed in triplicate.\n\nStep 3c: Variant Controls: Known pathogenic variants such as C418R and R256C were used as controls.",
          "judgment": "Yes",
          "reasoning": "Step 3a: Basic Controls and Replicates: The paper states that wild-type parkin was used as a control, and experiments were performed in triplicate.\n\nStep 3c: Variant Controls: The paper includes known pathogenic variants as controls, which strengthens the reliability of the functional evidence."
        },
        {
          "step_name": "Step 4: Apply evidence to individual variant interpretation",
          "extracted_paper_info": "Step 4b: No OddsPath Calculation: The study does not provide a direct OddsPath calculation but reports significant differences in p53 activity and expression.",
          "judgment": "Yes",
          "reasoning": "Step 4b: No OddsPath Calculation: While no OddsPath is calculated, the study provides sufficient statistical evidence of significant differences."
        }
      ],
      "final_evidence_strength": {
        "type": "Pathogenic",
        "strength": "PS3_moderate"
      },
      "overall_conclusion": "The R256C mutation significantly impairs parkin's ability to control p53 transcription, leading to increased p53 activity and expression. This is supported by robust experimental design and controls, indicating moderate pathogenic evidence."
    }
  ]
}